A trend in anticoagulant therapy for patients with cancer-associated venous thromboembolism

Read full text Summarise with VIRAT
Authors: Fumie Satoh, Norihiro Kondo, Kenyu Murata, T. Kawamura, Masahito Minakawa
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Objective: This study aimed to evaluate the efficacy and safety of primary therapeutic agents for treating cancer- associated venous thromboembolism (VTE). Material and Methods: Participants comprised 202 patients with active cancer and newly diagnosed VTE treated between 2014 and 2022. Patients were divided into two groups based on the treatment initiation period: early, Group E (2014–2018); or late, Group L (2019–2022). Outcomes were compared between groups. Results: The main anticoagulants used were edoxaban (58.5%) in Group E and rivaroxaban (36.5%) in Group L. Recurrent VTE occurred within 3 months in 7.7% (n=8) of Group E and 4.2% (n=4) of Group L. No significant differences were observed in death within 30 days, VTE-related deaths, hemorrhagic complications, or recurrent VTE. Although the overall number of deaths differed significantly between groups (Group E: 29 vs. Group L: 21; p

Fields of Study & Subjects

Venous Thromboembolism Diagnosis and Management Blood Coagulation and Thrombosis Mechanisms Atrial Fibrillation Management and Outcomes

Publication details

Journal / source
Institutional Repositories DataBase (IRDB)
Volume
76
Issue
1-4
Pages
17–24
Publication date
10 March 2026
Language
EN